Correlation Between Medigen Biotechnology and Ruentex Engineering

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Medigen Biotechnology and Ruentex Engineering at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medigen Biotechnology and Ruentex Engineering into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Medigen Biotechnology and Ruentex Engineering Construction, you can compare the effects of market volatilities on Medigen Biotechnology and Ruentex Engineering and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medigen Biotechnology with a short position of Ruentex Engineering. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medigen Biotechnology and Ruentex Engineering.

Diversification Opportunities for Medigen Biotechnology and Ruentex Engineering

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Medigen and Ruentex is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Medigen Biotechnology and Ruentex Engineering Constructi in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ruentex Engineering and Medigen Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medigen Biotechnology are associated (or correlated) with Ruentex Engineering. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ruentex Engineering has no effect on the direction of Medigen Biotechnology i.e., Medigen Biotechnology and Ruentex Engineering go up and down completely randomly.

Pair Corralation between Medigen Biotechnology and Ruentex Engineering

Assuming the 90 days trading horizon Medigen Biotechnology is expected to under-perform the Ruentex Engineering. In addition to that, Medigen Biotechnology is 1.04 times more volatile than Ruentex Engineering Construction. It trades about -0.27 of its total potential returns per unit of risk. Ruentex Engineering Construction is currently generating about -0.06 per unit of volatility. If you would invest  14,600  in Ruentex Engineering Construction on September 24, 2024 and sell it today you would lose (350.00) from holding Ruentex Engineering Construction or give up 2.4% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Medigen Biotechnology  vs.  Ruentex Engineering Constructi

 Performance 
       Timeline  
Medigen Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Ruentex Engineering 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Ruentex Engineering Construction are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Ruentex Engineering is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Medigen Biotechnology and Ruentex Engineering Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Medigen Biotechnology and Ruentex Engineering

The main advantage of trading using opposite Medigen Biotechnology and Ruentex Engineering positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medigen Biotechnology position performs unexpectedly, Ruentex Engineering can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ruentex Engineering will offset losses from the drop in Ruentex Engineering's long position.
The idea behind Medigen Biotechnology and Ruentex Engineering Construction pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Fundamental Analysis
View fundamental data based on most recent published financial statements